uniQure stock rises after positive Huntington’s disease gene therapy data

uniQure (QURE) shares surged over 220% in the past week following positive three-year follow-up data from its Phase 1/2 study of gene therapy AMT-130 for Huntington's disease, demonstrating a statistically significant 75% slowing of disease progression and a consistent safety profile. This strong data supports the company's plan for a Q1 2026 Biologics License Application filing under accelerated approval, with Goldman Sachs modeling potential peak global sales of $2.5 billion and multiple analysts upgrading price targets, despite a recent $200 million public offering.

Analysis

uniQure N.V. (QURE) has reported highly positive three-year follow-up data from its pivotal Phase 1/2 study of gene therapy AMT-130 for Huntington’s disease, serving as a significant de-risking event for the asset. The high-dose cohort demonstrated a statistically significant 75% mean slowing of disease progression and a 60% slowing in total functional capacity, supported by neurofilament light protein levels remaining below baseline. These results underpin the company's strategy to pursue a Biologics License Application (BLA) filing in Q1 2026 under an accelerated approval pathway, with a pre-BLA meeting with the FDA scheduled for Q4. The market has reacted strongly, with the stock surging over 220% in the past week to approach its 52-week high. Sell-side analysts have responded with significant price target upgrades; Leerink Partners raised its target to $68 and Stifel to $65, while Goldman Sachs projects a 90% probability of success and potential peak global sales of $2.5 billion, despite maintaining a Neutral rating. Concurrent with this clinical success, uniQure has announced a $200 million public offering, leveraging its strengthened valuation to fortify its balance sheet ahead of potential commercialization.

Key Decisions for Investors

• The positive and statistically significant Phase 1/2 data for AMT-130 has substantially de-risked the asset, and investors may view this as a strong validation of the long-term thesis, supported by analyst projections of a multi-billion dollar peak sales opportunity.
• Monitor the upcoming Q4 pre-BLA meeting with the FDA as the next key catalyst, but be aware of potential short-term volatility and dilution from the recent $200 million public offering following the stock's sharp appreciation.
• While price target upgrades from several analysts suggest further upside, Goldman Sachs's Neutral rating indicates a more cautious stance on valuation, prompting a need to weigh the significant long-term potential against the risk of entering a position near a 52-week high.